PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31699612-0	2019	Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants.	imatinib	60-68	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	133-140	
31699612-1	2019	To reveal insights into the inhibition of BCR-ABL and its mutants, structure-based computing methods, such as docking, molecular dynamics (MD) simulation, the molecular mechanics generalized born surface area (MMGBSA), and biological characterizations, were employed to analyze two main pharmacophore zones and two related regions of imatinib derivatives.	imatinib	334-342	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	42-49	
31699612-5	2019	The results of our structure-based analysis and biological characterization of imatinib derivatives towards the inhibition of wild-type BCR-ABL and its mutants may provide new ideas for the design of imatinib analogs with potent activity.	imatinib	79-87	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	136-143	
31699612-5	2019	The results of our structure-based analysis and biological characterization of imatinib derivatives towards the inhibition of wild-type BCR-ABL and its mutants may provide new ideas for the design of imatinib analogs with potent activity.	imatinib	200-208	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	136-143